Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEOP uplisting to AMEX - Feb 10th
http://www.businesswire.com/news/home/20110207006768/en/Neoprobe-Common-Stock-Approved-Listing-NYSE-Amex
Great timing! Thanks $$$eeker!
(NEOP) - Lymphoseek....
I got in this the other day at $2.67.
I'm sure you are aware since you traded it before, but Lymphoseek has a lot of advantages over the current blue dye/colloid method. I'm not too familiar with this stuff but it is my understanding that the current method is used as an "off-label" use and is not reimbursable from insurance, etc. Lymphoseek would have an advantage because it would be reimbursable by medicare and private insurers. Also, from the trial results it would appear Lymphoseek may have a "superiority" claim over the current methods also. This is important because all analyst targets and revenue estimates were mostly based on Lymphoseek selling for around $150-$200 a dose whereas the current method is more around $400-500.
In this case, either Lymphoseek could easily/quickly gain market share - or since they would be reimbursable and maybe superior - perhaps they could raise their selling point close to that of the blue dye - garnering far more revenue than some of the analyst had estimated.
Other advantages of lymphoseek are described by this excerpt.
"In pre-clinical and FDA clinical trials to date, Lymphoseek has demonstrated superior site clearance, clearing the injection site between four and eight times faster than the older Sulpher colloid products. Lymphoseek begins clearing as quickly as 15 minutes after injection, saving time in the operating room. In a direct comparison in clinical trials, five hours after injection 95% of the Sulpher Colloid based product still remained at the injection site, whereas 75% of Lymphoseek had cleared the site and migrated into the lymphatics."
Looking forward to the results to come out. This company should be valued higher based on Lymphoseek alone - not to mention the rest of the pipeline (Rigscan). I'm hopeful that they can uplist soon.
Colorofmoney: Do you currently still hold AVNR? Was curious as to how long you expect to hold it? It looks like they have assembled a great sales staff and began marketing Neudexta very well. I also think they have made the drug affordable which was a concern of mine before approval. I know there is some dispute as to the demand they will have. My Question is how long after the availability of Neudexta (which is this week I believe) until we get some sort of sales figure?
To me all signs point towards a good demand for the drug and since their is some debate - good sales numbers could propel AVNR substantially. Any thoughts? I hate to hold for too long as there are other places to be making $$ in BioLand if there are no catalyst here soon - but I do feel AVNR is a potentially safer longer term hold for those interested.
Lots of Cash - little debt - and good insider/institutional ownership which is a huge plus for me anytime. I like to see management that has an incentive to run the company in a way that best benefits the shareholders.
Thanks.
NEOP very good read for those interested in their lymphoseek technology.
http://www.tripointglobalresearch.com/research/NEOP/NEOP_Report_092210.pdf
(CORT) - Insider's hold 59% of shares and Institutions hold 20%. Not only that, they are accumulating more - huge direct purchase of nearly $3,000,000 on Jan 21 by a Director - insider holdings were up 30% - 6,200,000 shares last QTR.
Their drug is for Cushing's Syndrome which is not very common - so they were granted orphan drug status. The FDA said they needed to show a 20% response rate in trials. They had two different groups - one showed 60% and the other 43%. Currently no drugs on the market to compete with but Novartis has one in their pipeline as well.
They expect to file NDA this quarter. You hear a lot about takeovers and acquisitions but I personally have never been in a stock that actually had that happen. It is interesting how much the insider's are accumulating and the fact that CORT doesn't have much else going for them besides this drug.
Also recently sold some shares at $3.90 so plenty of cash on hand for the time being - which takes away the fear of another surprise offering anytime soon.
I am planning on holding at least until they file NDA which hopefully will be by the end of March. The chart looks good. It did break through to 50-day-MA which concerned me but it quickly fought back, especially after today. Looks like it may continue its uptrend. I don't like targets really but it looks like it should hit at least $4.50 range.
On another note - how about KV-A - as many bio stocks as I follow I never seem to get the ones that have that kind of gain =/
Have a good weekend all.
good article:
http://www.fool.com/investing/general/2010/12/23/corcept-may-have-hit-pay-dirt.aspx
AVNR conference call in the morning- NEOP possibly getting back to its uptrend after today. Big catalyst (1) uplisting (2) trial results within 30 days or so (3) filing of NDA afterwards
Also AVNR conference call in the morning-
Corcept Therapeutics Inc. (CORT) DD
Just some basic DD of what CORT is all about – I’m not advocating anyone to buy/sell. Disclaimer: I did buy a starter position @ $4.00 last Friday.
Stock Data
• Shares Outstanding – 72.38 M
• Float – 37.44 M
• Held By Insiders – 58.90%
• Held By Institutions – 20.10%
• Shares Short ~ 2.69 M
• Short % of Float – 8.10%
Financial Data
• Debt – None
• Cash – Roughly $25 M
• Revenue – None
Analyst Targets (Note: I typically put little faith into analyst targets)
• Piper Jaffray - $7.40
• Stifel Nicolaus - $7.00
• JMP Securities - $7.00
Catalyst
-Filing of NDA by end of 1st QTR
Corcept’s product pipeline is centered around the development of CORLUX. CORLUX is designed for the treatment of Cushing’s Syndrome.
----A little background on Cushing’s Syndrome----
Cushing’s syndrome is a hormone disorder that develops because of high levels of cortisol in the blood. Cushing’s Sydrome is caused by taking glucocorticoid drugs(hormone, think steroids) or by tumors. Typically it is caused from hormones that come from outside the body (exogenous), typically from glucocorticoids prescribed by doctors for other diseases. Symptoms include weight gain, excess sweating, thinning of the skin and hemorrhage due to the stretching from weight gain, sore joints, easy bruising, etc. Treatment usually is to reduce the source of the outside source to the lowest amount possible.
As for endogenous Cushing’s Syndrome, which is caused by tumors that secrete excess cortisol, there are limited treatment options. Treatment options may include surgery, radiation, chemotherapy, or cortisol-inhibiting drugs. 80% of patients have surgery to have the tumors removed – but nearly half fail the surgery or have a lapse at a later date.
If surgery or radiation is unsuccessful, there are no FDA approved treatments available – most just take drugs to address symptoms.
CORLUX has been granted Orphan Drug Designation by the FDA for the treatment of endogenous Cushing’s syndrome.
----Phase 3 Study----
Phase 3 Data was announced in December of 2010. The study was a 50-patient open-label study with Cushing’s syndrome patients who were not elgible, failed, or relapsed from surgery. The study evaluated the response of two patient groups to CORLUX treatment, one included patients who were (1)glucose intolerant and one included patients who were (2)hypertensive. Statistically significant improvement in the primary endpoint was achieved for both groups: with 60% and 38% responding in the glucose intolerant group and hypertensive group, respectively. Statistically significant benefit was also achieved in the key secondary endpoint of global clinical improvement, with 87% of patients responding. An initial review of safety data indicates that CORLUX was well tolerated by Cushing’s Syndrome patients in this Phase 3 study. The protocol for the trial dictates that if a sufficient number of patients in either the glucose intolerant group or the hypertension group are responders, such that the lower limit of the exact one-sided 95% binomial confidence interval (CI) for the responder rate is greater than 20%, then the trial will have demonstrated efficacy for the treatment of Cushing's Syndrome.
Corcept Therapeutics is planning on filing a NDA to the FDA for Corlux by the end of the first quarter of 2011.
You can read more about the phase 3 results here http://www.corcept.com/news_events/pr_1292984884
AVNR confirms launch
http://finance.yahoo.com/news/AVANIR-Pharmaceuticals-prnews-1980500256.html?x=0&.v=1
You too crutch - looking forward to conference call monday - and I am with you on OREX I've stayed away from that - I did pick up some CORT today on the drop at $4.00 - I'm liking the chart
Some basic CORT highlights
They have NDA for "Corlux" - for cushing's syndrome in the first qtr. '11
~59% held by insiders
~20% held by institutions - these two factors are very high on my priority list - i like to see management with a vested interest
Target price by most analyst of $6.50 - $7.4ish
possibly on pace for FDA prioity review in 4th qtr 2011
on Jan 11th they announced positive results on key secondary endpoint in a phase 3 study of Corlux - info on that can be read here http://www.corcept.com/news_events/pr_1294733855
on December 22nd they announced that primary endpoint was achieved for both groups in phase 3 study - info on that can be read here http://www.corcept.com/news_events/pr_1292984884
Estimated 20,000 people with Cushings in the U.S. Analysis have thrown around some numbers of $225M in sales for their target prices
There has been some speculation that they may market this drug on their own since it is somewhat specialized smaller market for a rare disease
This is all very preliminary research on my part - focused on DEPO for the next few days - but I like what I've found so far.
Been focused a lot on DEPO and haven't done much research lately - I still like NEOP a lot and am in BPAX - I will post some other thursday night.
Best website for data about how many shares are short on a stock?? TIA
Gekko's Bulls and Bears for Dm-1796
http://www.gekkowire.com/
Solid day for NEOP - was hoping it would stay down for a bit until I could get some funds from trading DEPO after this week. It should be an interesting quarter for NEOP
Pcrutch - What are your thoughts on DEPO this week?
I typically do not hold through approval but I like all I've read about DEPO. My concern is always the unexpected that we never had access to knowing. ABT really screwed my gains up this week.
BTW - I think NEOP is poised for some action - bought into it for the first time last week.
Gekko piece today on DEPO http://www.gekkowire.com/?p=5828
I like the volume lately. Stock doesn't get a lot of talk on many of the main bio-tech messageboards/websites but it has slowly moved itself up. Hopefully we still have some room to move. GLTA
Does anyone have a good link to an FDA/events calendar? I had a good one bookmarked and somehow lost it. TIA
I have sold my position - and bought options last week with half of the profits I made and will be holding those through approval. I would have held my shares through approval but I am in law school racking up huge bills and just am not in a position to risk losing money no matter how good I felt about approval. I was in SOMX and meant to sell before approval but woke up and it had been approved and made a ton - there is a lot of money that can be made on approvals so good luck to all of us.
It is allowing them to presumably get a lot of resumes from applicants so they can be prepared to hire if approved. I don't expect they have actually hired a full sales team yet, just have posted the listings. But I think it is a good sign, shows they expect approval and are ready to make the next move. Upon approval they should be able to fill the needed positions quicker than if they had waited to post all these jobs listings.
Just my opinion. I could be wrong.
Agree with every part of your post.
100K share buy after hours
Agreed - chart is looking good again assuming we close somewhere near where it is trading now.
-Joe